Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERENOME, INC.CTYX · Entity 7637 | Director | November 28, 2017 | February 09, 2018 |
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director | May 01, 2023 | May 02, 2023 |
| Fresh Tracks Therapeutics, Inc.BBI · Entity 90076 | Director | May 17, 2022 | May 17, 2022 |
| NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655 | Director | May 27, 2026 | May 29, 2026 |
| RIGEL PHARMACEUTICALS INCRIGL · Entity 2423 | Director | May 26, 2023 | July 12, 2023 |
| Travere Therapeutics, Inc.TVTX · Entity 1562 | Director | August 17, 2026 | August 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERENOME, INC.
Report date November 28, 2017 · Filed February 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Subscription Rights (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1,000.00 · Expires 2017-11-21 | Direct | 0 |
Reported balance
After 2017-11-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-11-28 · Other · Disposed 1 · Balance 0 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. |
| Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.33 | Direct | 1 |
Reported balance
After 2017-11-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-11-28 · Other · Acquired 1 · Balance 1 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2: The Series B Preferred Stock has no expiration date. |
| Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.33 · Expires 2020-05-28 | Direct | 1,800 |
Reported balance
After 2017-11-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-28 · Other · Acquired 1,800 · Balance 1,800 F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000.
F2: The Series B Preferred Stock has no expiration date.
F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.3333 per share from the date the Company receives stockholder approval of an amendment to its certificate of incorporation to increase its authorized shares of common stock through May 28, 2020.
Eledon Pharmaceuticals, Inc.
Report date May 01, 2023 · Filed May 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2033-05-01 | Direct | 150,437 |
Reported balance
After 2023-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-01 · Grant · Acquired 150,437 · Balance 150,437 F1: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025.
Fresh Tracks Therapeutics, Inc.
Report date May 17, 2022 · Filed May 17, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.19 · Expires 2032-05-17 | Direct | 65,000 |
Reported balance
After 2022-05-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-17 · Grant · Acquired 65,000 · Balance 65,000 |
NEUROCRINE BIOSCIENCES INC
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restriced Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,284 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 1,284 · Balance 1,284 F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2: The RSUs will vest in full on May 27, 2027. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $155.83 · Expires 2036-05-27 | Direct | 2,624 |
Reported balance
After 2026-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-27 · Grant · Acquired 2,624 · Balance 2,624 F3: Option vests in 12 monthly installments beginning June 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.
F2: The RSUs will vest in full on May 27, 2027.
F3: Option vests in 12 monthly installments beginning June 27, 2026.
RIGEL PHARMACEUTICALS INC
Report date May 26, 2023 · Filed July 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 75,000 |
Reported balance
After 2023-05-26 transaction · row 1
1 source rowRow 1 · 2023-05-26 · Grant · Acquired 25,000 · Balance 75,000 F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2033-05-26 | Direct | 30,000 |
Reported balance
After 2023-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-26 · Grant · Acquired 30,000 · Balance 30,000 F2: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
F2: The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.
Travere Therapeutics, Inc.
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 61,500 |
Ending reported balance
After 2026-08-18 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-08-17 · Exercise / conversion · Acquired 5,000 · Balance 66,500 Row 2 · 2026-08-17 · Sale · Disposed 1,900 · Balance 64,600 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F2: The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 3 · 2026-08-17 · Sale · Disposed 2,600 · Balance 62,000 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F3: The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 4 · 2026-08-17 · Sale · Disposed 500 · Balance 61,500 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F4: The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-08-18 · Exercise / conversion · Acquired 5,000 · Balance 66,500 Row 6 · 2026-08-18 · Sale · Disposed 4,100 · Balance 62,400 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F5: The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 7 · 2026-08-18 · Sale · Disposed 900 · Balance 61,500 F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F6: The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2027-05-17 | Direct | 5,000 |
Reported balance
After 2026-08-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-17 · Exercise / conversion · Disposed 5,000 · Balance 5,000 F7: The stock option is fully vested and exercisable. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-08-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-08-18 · Exercise / conversion · Disposed 5,000 · Balance 0 F7: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on May 18, 2026 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
F2: The weighted average sale price for the transaction reported was $62.5289, and the range of prices were between $62.00 and $62.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $63.4999, and the range of prices were between $63.01 and $63.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $64.1620, and the range of prices were between $64.04 and $64.25. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The weighted average sale price for the transaction reported was $63.2659, and the range of prices were between $62.76 and $63.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F6: The weighted average sale price for the transaction reported was $63.8557, and the range of prices were between $63.77 and $64.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F7: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 28, 2017 Filed Feb 9, 2018 21:54 UTC | CERENOME, INC. CTYX · Entity 7637 | OtherSeries B Preferred Stock · Derivative | 1 | Not disclosed Strike: $0.33 | Not disclosed |
DisclosureSEC source: 0001209191-18-008901 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 3,000 shares Expires not disclosed F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F2 · derivative.expiration_date: The Series B Preferred Stock has no expiration date. Read SEC document |
| November 28, 2017 Filed Feb 9, 2018 21:54 UTC | CERENOME, INC. CTYX · Entity 7637 | OtherSubscription Rights (Right to Buy) · Derivative | 1 | Not disclosed Strike: $1,000.00 | Not disclosed |
DisclosureSEC source: 0001209191-18-008901 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: see footnote · Not disclosed shares Expires 2017-11-21 F1 · price: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. F1 · derivative.underlying_shares: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, In. (the "Company") to all holders of the Company's common stock on October 27, 2017. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series B Preferred Stock (convertible into 3,000 shares of the Company's common stock) and 1,800 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 20:07 UTC | Eledon Pharmaceuticals, Inc. NVUS · Entity 6160 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $5.85 | $0.00 |
DisclosureSEC source: 0000899243-17-017767 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-06-30 F1 · derivative.exercise_date: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock. The shares will vest ratably each quarter over three years beginning on June 30, 2017. Read SEC document |
| May 25, 2017 Filed May 30, 2017 17:40 UTC | Fresh Tracks Therapeutics, Inc. VICL · Entity 90076 | GrantNonstatutory Stock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-17-036193 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock, $.01 par value · 6,500 shares Expires 2027-05-24 F1 · derivative.exercise_date: The date in this field is approximate. These options are exercisable at the date of the next annual meeting of stockholders. The date of the meeting has not been set, but is expected to occur in May 2018. Read SEC document |
| May 22, 2017 Filed Jun 8, 2017 22:29 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | GrantStock Option · Derivative | 15,000 | $0.00 Strike: $53.64 | $0.00 |
DisclosureSEC source: 0001209191-17-038628 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-22 F1 · derivative.exercise_date: Option vests in 12 equal monthly installments beginning June 22, 2017. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:19 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.44 | $0.00 |
DisclosureSEC source: 0001209191-17-033723 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-16 F1 · derivative.exercise_date: The option shall vest in 4 equal quarterly installments following the date of grant. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:19 UTC | Travere Therapeutics, Inc. RTRX · Entity 1562 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033723 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 Read SEC document |
| May 12, 2017 Filed May 12, 2017 21:58 UTC | RIGEL PHARMACEUTICALS INC RIGL · Entity 2423 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.61 | $0.00 |
DisclosureSEC source: 0001179110-17-007129 · edgar.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-05-12 F1 · derivative.exercise_date: The shares vest monthly over twelve (12) months from the date of grant. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001209191-17-011233 · doc4.xml · derivative · entry 2 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 23:52 UTC | NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655 | Exercise / conversionCommon Stock | 15,000 | $3.40 | $51,000.00 |
DisclosureSEC source: 0001209191-17-011233 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The share issuance reported on Table I reflects shares issued upon the exercise of options granted on May 25, 2010, which, if unexercised would have expired on May 25, 2017. The option exercises are reported on Table II. Read SEC document |
| January 26, 2017 Filed Jan 27, 2017 22:49 UTC | CERENOME, INC. CTYX · Entity 7637 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001209191-17-005974 · doc4.xml · derivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-26 F1 · derivative.exercise_price: The reporting person received a non-qualified stock option granted under the Issuer's 2014 Equity Incentive Plan. The exercise price per share to be paid by the reporting person at the time the option is exercised is the closing sale price of the Issuer's Common Stock on the NASDAQ Stock Market as of the date of the grant. The closing sale price on the date of the grant was $1.56. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 16:35 UTC | Fresh Tracks Therapeutics, Inc. VICL · Entity 90076 | SaleCommon Stock $.01 par value | 7,078 | $2.30 | $16,248.26 |
DisclosureSEC source: 0001209191-16-153905 · doc4.xml · nonDerivative · entry 1 LYONS GARY A · CIK 0001123343 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,828 F1 · price: Represents a weighted average price per share. The prices actually ranged from $2.25 to $2.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2 · balance_after: Share amounts have been adjusted to give effect to a 1-for-10 reverse stock split on May 26, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.